Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01018030
First received: November 19, 2009
Last updated: June 20, 2013
Last verified: April 2011

November 19, 2009
June 20, 2013
January 2010
July 2010   (final data collection date for primary outcome measure)
Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period (Weeks 1-2) [ Time Frame: Baseline and entire treatment period (up to 2 weeks) ] [ Designated as safety issue: No ]
The MSS was calculated as the sum of 3 individual symptom scores for nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip. Daily MSS was calculated as the average of the morning (AM) and evening (PM) MSS. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The total score ranged from 0 to 9. Change from baseline was calculated as the daily MSS averaged over the entire treatment period minus daily MSS over the baseline period (defined as the average daily MSS over the last 3 days prior to randomization).
Mean change from baseline in daily Major Symptom Score (sum of three individual symptom scores for nasal congestion, sinus headache/pressure or facial pain/pressure, and postnasal drip) over the entire treatment period [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01018030 on ClinicalTrials.gov Archive Site
  • First Time to Symptom Improvement [ Time Frame: Entire treatment period (up to 2 weeks) ] [ Designated as safety issue: No ]
    Symptom improvement was defined as symptom scores less than or equal to 1 (i.e., mild or no symptoms) for all three major symptoms (nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip) on 2 consecutive 12-hour assessments. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe.
  • Mean Change From Baseline Over the Entire Treatment Period in AM MSS [ Time Frame: Baseline and entire treatment period (up to 2 weeks) ] [ Designated as safety issue: No ]
    Mean change from baseline in MSS for nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip as measured in the morning (AM) was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The total score ranged from 0 to 9. Change from baseline in AM MSS was calculated as the AM MSS averaged over the entire treatment period minus the AM MSS over the baseline period (defined as the average AM MSS over the last 3 days prior to randomization).
  • Mean Change From Baseline Over the Entire Treatment Period in PM MSS [ Time Frame: Baseline and entire treatment period (up to 2 weeks) ] [ Designated as safety issue: No ]
    Mean change from baseline in MSS for nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip as measured in the evening (PM) was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The total score ranged from 0 to 9. Change from baseline in PM MSS was calculated as the PM MSS averaged over the entire treatment period minus the PM MSS over the baseline period (defined as the average PM MSS over the last 3 days prior to randomization).
  • Mean Change From Baseline Over the Entire Treatment Period in the Daily Nasal Congestion/Stuffiness Score [ Time Frame: Baseline and entire treatment period (up to 2 weeks) ] [ Designated as safety issue: No ]
    Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the daily nasal congestion/stuffiness score was calculated as the daily score averaged over the entire treatment period minus the daily score over the baseline period (defined as the average daily score over the last 3 days prior to randomization).
  • Mean Change From Baseline Over the Entire Treatment Period in the AM Nasal Congestion/Stuffiness Score [ Time Frame: Baseline and entire treatment period (up to 2 weeks) ] [ Designated as safety issue: No ]
    Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the AM nasal congestion/stuffiness score was calculated as the AM score averaged over the entire treatment period minus the AM score over the baseline period (defined as the average AM score over the last 3 days prior to randomization).
  • Mean Change From Baseline Over the Entire Treatment Period in the PM Nasal Congestion/Stuffiness Score [ Time Frame: Baseline and entire treatment period (up to 2 weeks) ] [ Designated as safety issue: No ]
    Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the PM nasal congestion/stuffiness score was calculated as the PM score averaged over the entire treatment period minus the PM score over the baseline period (defined as the average PM score over the last 3 days prior to randomization).
  • Mean Change From Baseline Over the Entire Treatment Period in the Daily Sinus Headache/Pressure or Facial Pain/Pressure Score [ Time Frame: Baseline and entire treatment period (up to 2 weeks) ] [ Designated as safety issue: No ]
    Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the daily sinus headache/pressure or facial pain/pressure score was calculated as the daily score averaged over the entire treatment period minus the daily score over the baseline period (defined as the average daily score over the last 3 days prior to randomization).
  • Mean Change From Baseline Over the Entire Treatment Period in the AM Sinus Headache/Pressure or Facial Pain/Pressure Score [ Time Frame: Baseline and entire treatment period (up to 2 weeks) ] [ Designated as safety issue: No ]
    Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the AM sinus headache/pressure or facial pain/pressure score was calculated as the AM score averaged over the entire treatment period minus the AM score over the baseline period (defined as the average AM score over the last 3 days prior to randomization).
  • Mean Change From Baseline Over the Entire Treatment Period in the PM Sinus Headache/Pressure or Facial Pain/Pressure Score [ Time Frame: Baseline and entire treatment period (up to 2 weeks) ] [ Designated as safety issue: No ]
    Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the PM sinus headache/pressure or facial pain/pressure score was calculated as the PM score averaged over the entire treatment period minus the PM score over the baseline period (defined as the average PM score over the last 3 days prior to randomization).
  • Mean Change From Baseline Over the Entire Treatment Period in the Daily Postnasal Drip Score [ Time Frame: Baseline and entire treatment period (up to 2 weeks) ] [ Designated as safety issue: No ]
    Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the daily postnasal drip score was calculated as the daily postnasal drip score averaged over the entire treatment period minus the daily postnasal drip score over the baseline period (defined as the average daily postnasal drip score over the last 3 days prior to randomization).
  • Mean Change From Baseline Over the Entire Treatment Period in the AM Postnasal Drip Score [ Time Frame: Baseline and entire treatment period (up to 2 weeks) ] [ Designated as safety issue: No ]
    Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the AM postnasal drip score was calculated as the AM postnasal drip score averaged over the entire treatment period minus the AM postnasal drip score over the baseline period (defined as the average AM postnasal drip score over the last 3 days prior to randomization).
  • Mean Change From Baseline Over the Entire Treatment Period in the PM Postnasal Drip Score [ Time Frame: Baseline and entire treatment period (up to 2 weeks) ] [ Designated as safety issue: No ]
    Mean change from baseline was calculated as the Week 1-2 value minus the baseline value. Each individual symptom was scored on a scale of 0 to 3: 0=none; 1=mild; 2=moderate; 3=severe. The score ranged from 0 to 3. Change from baseline in the PM postnasal drip score was calculated as the PM postnasal drip score averaged over the entire treatment period minus the PM postnasal drip score over the baseline period (defined as the average PM postnasal drip score over the last 3 days prior to randomization).
  • Number of Participants Who Require the Use of an Antibiotic Due to the Development of Fulminant Bacterial Rhinosinusitis (FBRS) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    Participants who required the use of an antibiotic due to the development of FBRS during the 2-week treatment period and the 2-week follow-up period were included in the analysis.
  • First time to symptom improvement (defined as reduction of individual symptom scores of nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip) [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
  • Mean change from baseline over the entire treatment period in AM and PM MSS and daily, AM, and PM individual symptom scores [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]
  • Percentage of subjects who require the use of an antibiotic during the study [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis
A Randomized, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, 2-week Treatment Study to Evaluate the Safety and Efficacy of Fluticasone Furoate Nasal Spray 110 Mcg in the Treatment in the Treatment of Uncomplicated Acute Rhinosinusitis in Adults and Adolescents >= 12 Years of Age

The purpose of this study is to assess the safety and efficacy of fluticasone furoate nasal spray (FFNS), without the use of an antibiotic, in the treatment of adult and adolescent subjects who are 12 years of age and older with uncomplicated acute rhinosinusitis (ARS).

- Rationale - Acute rhinosinusitis (ARS) is a condition caused by inflammation of the nose and the paranasal sinuses that generally lasts up to 4 weeks. Despite ARS being a self-limiting condition, untreated or inadequately treated sinus infection can lead to the development of complications. Uncomplicated ARS is a subset of ARS and is distinguished from the common cold by the persistence or the worsening of sinus inflammation after the usual period for recovery of viral infection of the nasal cavity (i.e., 10 days). Clinically the difference is based on the following criteria: symptoms are present at least 10 days but less than 4 weeks beyond the onset of upper respiratory symptoms OR symptoms worsen after 5 days from their onset.

In the primary care settings, ARS is often treated empirically with antibiotics although they are shown to provide limited benefit in the uncomplicated ARS population. Alternatively, the use of an intranasal corticosteroid (INS) to control symptoms of uncomplicated ARS is plausible based on clinically proven ability to reduce inflammation and mucosal swelling.

This study is a phase II study.

  • Objective - The objective of this study is to evaluate the safety and efficacy of two doses of FFNS (110 mcg once daily and 110 mcg twice daily) compared to placebo as monotherapy in the treatment of adult and adolescent subjects 12 years of age and older with uncomplicated ARS.
  • Study Design - This is a randomized, double-blind, placebo controlled, parallel group, multi-centre, 2-week treatment study. The study includes a 2-week post-treatment follow-up period.

Approximately 720 subjects will be randomized to one of three treatment groups for a period of 14 days: FFNS 110 mcg QD, FFNS 110 mcg BID, and placebo nasal spray.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Sinusitis, Acute
  • Drug: FFNS 110 mcg QD
    Active Nasal Spray (AM) and Placebo Nasal Spray (PM)
  • Drug: FFNS 110 mcg BID
    Active Nasal Spray (AM) and Active Nasal Spray (PM)
  • Drug: Placebo Nasal Spray
    Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)
  • Experimental: FFNS 110 mcg QD
    Intervention: Drug: FFNS 110 mcg QD
  • Experimental: FFNS 110 mcg BID
    Intervention: Drug: FFNS 110 mcg BID
  • Placebo Comparator: Placebo Nasal Spray
    Intervention: Drug: Placebo Nasal Spray
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
741
July 2010
July 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Informed consent
  2. Outpatient
  3. Age (>= 18 years at Visit 1 for Russia, Ukraine, and Germany; >= 12 years at Visit 2 for all other countries)
  4. Diagnosis of uncomplicated acute rhinosinusitis
  5. Ability and willingness to comply with study procedures and restrictions.
  6. Male or eligible female - Female subjects should not be enrolled if they plan to become pregnant during the time of study participation; To be eligible for entry into the study, females of childbearing potential must commit to the consistent and correct use of an acceptable method of birth control.
  7. Literate

Exclusion Criteria:

  1. Based on the investigator's clinical judgement, subject has fulminant bacterial rhinosinusitis during the screening period including Visits 1 and 2.
  2. A history of acute rhinosinusitis within 12 weeks prior to the current episode as determined by the investigator
  3. Current or a history of other sinonasal conditions (e.g., chronic or recurrent rhinosinusitis, non-allergic rhinitis) within 3 years prior to Visit 1 as determined by the investigator
  4. Symptomatic perennial or seasonal allergic rhinitis prior to ARS episode, or allergy to seasonal allergens likely to be present during the study period (as determined by documented skin prick test or in vitro blood test).
  5. Significant concomitant medical conditions
  6. Subjects with planned elective surgery, vacation or other event during the study period which could prevent the subject from participating in the study according to protocol specifications
  7. Use of antibiotics within 30 days prior to Visit 1 for sinopulmonary infections.
  8. Use of antiviral medications such as zanamivir and oseltamivir within 30 days prior to Visit 1
  9. Use of analgesics or antipyretics within 1 day prior to Visit 1
  10. Known hypersensitivity or allergy to corticosteroids or any excipients in the product
  11. Use of corticosteroids, defined as:
  12. Use of any other medications that may affect nasal symptoms
  13. Use of immunosuppressive medications eight weeks prior to screening and during the study
  14. Immunotherapy
  15. Use of any medications that significantly inhibit the cytochrome P450 subfamily enzyme CYP3A4, including ritonavir and ketoconazole
  16. Clinical trial/experimental medication experience
  17. Positive pregnancy test or inconclusive pregnancy test or female who is breastfeeding
  18. Affiliation with investigational site
  19. Current tobacco use
  20. Chicken pox or measles
Both
12 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Czech Republic,   Netherlands,   Norway,   Sweden
 
NCT01018030
113203
No
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP